Combination of a CD26 Inhibitor, G-CSF, and Short-term Immunosuppressants Modulates Allotransplant Survival and Immunoregulation in a Rodent Hindlimb Allotransplant Model

Abstract

Original Basic Science-GeneralBackground. Recent studies have demonstrated that inhibition of CD26 potentiates stromal cell-derived factor-1α (SDF-1α), promotes tissue regeneration, and suppresses the rejection of organ transplants. This study investigated whether the combination of a CD26 inhibitor (CD26i) with granulocyte colony-stimulating factor (G-CSF) and short-term immunosuppressants modulates vascularized composite tissue allotransplant survival in a rodent orthotopic hindlimb allotransplant model. Methods. The hindlimb allotransplantation from Brown-Norway to Lewis rats was divided into 4 groups. Group 1 (controls) did not receive any treatment. Group 2 was treated with short-term antilymphocyte serum (ALS) and cyclosporine-A (CsA). Group 3 was administrated CD26i and G-CSF. Group 4 received a combination of CD26i/G-CSF/ALS/CsA. Each subgroup comprised 10 rats. Peripheral blood and sampling of transplanted tissues were collected for immunological and histological analysis. Results. The results revealed that allotransplant survival was found to be significantly prolonged in group 4 with CD26i/G-CSF/ALS/CsA treatment compared with those in the other groups. The interleukin-10 and transforming growth factor-βl levels, the percentage of CD4 + /CD25 + /FoxP3 + T cells, as well as the levels of SDF-1α expressions were significantly increased in group 4 compared with those in the other groups. Group 4 revealed a statistical increase in the percentage of donor cells (RT1 n ) expression in the recipient peripheral blood, and the mixed lymphocyte reaction showed hyporesponsiveness of the T cells to donor alloantigens. Conclusion. The combination of CD26i/G-CSF and short-term immunosuppressants prolongs allotransplant survival by inducing immunoregulatory effects and enhancing the percentage of SDF-1α expression. This immunomodulatory approach has great potential as a strategy to increase vascularized composite allotransplantation survival.

Effect of intrauterine perfusion of granular leukocyte-colony stimulating factor on the outcome of frozen embryo transfer

“…G-CSF, a cytokine that can stimulate the differentiation of bone marrow hematopoietic cells, was initially mainly used in the treatment of blood system diseases associated with leukopenia; recently, it was found to promote angiogenesis and immune regulation and inhibit inflammatory reactions with overt neurotrophic effect, and has been widely applied in nervous, cardiovascular and endocrine system diseases[ 39 ].The expression of G-CSF receptor was found in ovarian granulosa cells, the endometrium and the placenta. G-CSF plays an important role in pregnancy.…”

DPP3: From biomarker to therapeutic target of cardiovascular diseases

“…Among them, DPP4 inhibitors, such as vildagliptin and sitagliptin, can reduce the level of blood glucose by enhancing the effects of the insulin-stimulating peptides glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-stimulating polypeptide (GIP). Furthermore, this class of drugs is used to treat type 2 diabetes and improve glycemic control ( 28 ). Similarly, a non-selective inhibitor of DPP, Val-boroPro (talabostat), can also treat prostate cancer by affecting fibroblast activation protein via reducing angiogenesis and inhibiting tumor proliferation and invasion ( 29 ).…”